Replimune Group Inc’s recent filing unveils that its Chief Executive Officer Patel Sushil unloaded Company’s shares for reported $0.12 million on Dec 16 ’24. In the deal valued at $12.42 per share,10,000 shares were sold. As a result of this transaction, Patel Sushil now holds 202,014 shares worth roughly $2.73 million.
Then, Sushil Patel bought 15,000 shares, generating $188,550 in total proceeds.
Before that, Xynos Konstantinos sold 7,246 shares. Replimune Group Inc shares valued at $78,112 were divested by the Chief Medical Officer at a price of $10.78 per share. As a result of the transaction, Xynos Konstantinos now holds 109,885 shares, worth roughly $1.48 million.
ROTH MKM initiated its Replimune Group Inc [REPL] rating to a Buy in a research note published on August 28, 2024; the price target was $17. Piper Sandler began covering REPL with “an Overweight” recommendation on November 19, 2021.
Price Performance Review of REPL
On Tuesday, Replimune Group Inc [NASDAQ:REPL] saw its stock fall -0.88% to $13.49. Over the last five days, the stock has lost -3.85%. Replimune Group Inc shares have risen nearly 11.40% since the year began. Nevertheless, the stocks have risen 69.69% over the past one year. While a 52-week high of $17.00 was reached on 02/21/25, a 52-week low of $4.92 was recorded on 01/13/25. SMA at 50 days reached $12.77, while 200 days put it at $10.74.
Levels Of Support And Resistance For REPL Stock
The 24-hour chart illustrates a support level at 13.15, which if violated will result in even more drops to 12.80. On the upside, there is a resistance level at 13.78. A further resistance level may holdings at 14.06. The Relative Strength Index (RSI) on the 14-day chart is 50.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.60%. Stochastics %K at 54.75% indicates the stock is a holding.
The most recent change occurred on November 17, 2020 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
